Show simple item record

dc.contributor.authorStensvold, Einar
dc.contributor.authorMyklebust, Tor Åge
dc.contributor.authorCappelen, Johan
dc.contributor.authorDue-Tønnessen, Bernt Johan
dc.contributor.authorDue-Tønnessen, Paulina
dc.contributor.authorKepka, Aleksandra
dc.contributor.authorJohannessen, Tom Børge
dc.contributor.authorKrossnes, Bård Kronen
dc.contributor.authorLundar, Tryggve
dc.contributor.authorMaric, Snezana
dc.contributor.authorMiletic, Hrvoje
dc.contributor.authorMoholdt, Viggo
dc.contributor.authorMyrmel, Kristin Smistad
dc.contributor.authorNordberg, Terje
dc.contributor.authorRydland, Jana
dc.contributor.authorStokland, Tore
dc.contributor.authorSolem, Kristin
dc.contributor.authorSolheim, Ole
dc.contributor.authorTorsvik, Ingrid Kristin
dc.contributor.authorWikran, Gry Charlotte
dc.contributor.authorZeller, Bernward
dc.contributor.authorWesenberg, Finn
dc.contributor.authorBechensteen, Anne Grete
dc.contributor.authorBrandal, Petter
dc.date.accessioned2022-12-19T14:40:40Z
dc.date.available2022-12-19T14:40:40Z
dc.date.created2019-11-12T14:21:19Z
dc.date.issued2019
dc.identifier.citationPediatric Blood & Cancer. 2019, 66:e27910 1-12.en_US
dc.identifier.issn1545-5009
dc.identifier.urihttps://hdl.handle.net/11250/3038656
dc.description.abstractBackground: A previous study based on Norwegian Cancer Registry data suggested regional differences in overall survival (OS) after treatment for medulloblastoma (MB) and supratentorial primitive neuroectodermal tumor (CNS-PNET) in Norway. The purpose of the present study was to confirm in an extended cohort whether there were regional differences in outcome or not, and if so try to identify possible explanations. Material and methods: Data from patients aged 0–20 years diagnosed with and treated for MB/CNS-PNET at all four university hospitals in Norway from 1974 to 2013 were collected and compared. Results: Of 266 identified patients, 251 fulfilled inclusion criteria. MB was diagnosed in 200 and CNS-PNET in 51 patients. Five-year OS and event-free survival (EFS) were 59% and 52%, respectively. There was a significant difference in five-year OS and EFS between MB and CNS-PNET patients; 62% versus 47% (P = 0.007) and 57% versus 35% (P < 0.001). In multivariable analysis, two factors were found to significantly contribute to improved five-year OS and EFS, whereas one factor contributed to improved five-year OS only. Gross total resection (GTR) versus non-GTR (hazard ratio [HR] 0.53, P = 0.003; HR 0.46, P < 0.001) and cerebrospinal irradiation (CSI) versus non-CSI (HR 0.24, P < 0.001; HR 0.28, P < 0.001) for both, and treatment outside Oslo University Hospital for OS only (HR 0.64, P = 0.048). Conclusion: Survival was comparable with data from other population-based studies, and the importance of GTR and CSI was confirmed. The cause for regional survival differences could not be identified.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleChildren treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survivalen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-12en_US
dc.source.volume66:e27910en_US
dc.source.journalPediatric Blood & Canceren_US
dc.identifier.doi10.1002/pbc.27910
dc.identifier.cristin1746611
cristin.unitcode1920,16,0,0
cristin.unitcode1920,14,0,0
cristin.unitcode1920,4,0,0
cristin.unitcode1920,1,0,0
cristin.unitnameNevroklinikken
cristin.unitnameLaboratoriemedisinsk klinikk
cristin.unitnameKlinikk for bildediagnostikk
cristin.unitnameBarne- og ungdomsklinikken
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal